SAN DIEGO, May 3, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report first quarter 2017 results after Nasdaq market close on
Tuesday, May 9, 2017.
Neurocrine will then host a live conference call and webcast
to discuss its financial results and provide a Company update
Tuesday afternoon, May 9, 2017, at
5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Participants can access the live conference call by dialing
877-876-9177 (US) or 785-424-1666 (International) using the
conference ID: NBIX. The call can also be accessed via the webcast
through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further
information on this announcement, please contact the Investor
Relations Department at Neurocrine Biosciences at (858) 617-7600.
A replay of the conference call will be available
approximately one hour after the conclusion of the call by dialing
800-839-4514 (US) or 402-220-2680 (International) using the
conference ID: NBIX. The call will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a San
Diego based biotechnology company focused on neurologic,
psychiatric and endocrine related disorders. In April of 2017 the
FDA approved INGREZZA™ (valbenazine) capsules for the treatment of
adults with tardive dyskinesia (TD). INGREZZA is a novel,
selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and
is the first and only FDA-approved product indicated for the
treatment of adults with TD. The Company markets INGREZZA in
the United States. The Company's
three late-stage clinical programs are: elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc.; opicapone, a novel, once-daily,
peripherally-acting, highly-selective catechol-o-methyltransferase
inhibitor under investigation as adjunct therapy to levodopa in
Parkinson's patients; and INGREZZA™ (valbenazine), a novel,
once-daily, selective VMAT2 inhibitor under investigation for the
treatment of Tourette Syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-first-quarter-2017-results-300447578.html
SOURCE Neurocrine Biosciences, Inc.